What's Happening?
OneCyte and Kemp Proteins have announced a strategic partnership aimed at improving cell line development for biopharmaceutical companies. This collaboration combines OneCyte's high-throughput single-cell
analysis technology with Kemp Proteins' molecular engineering capabilities, including their machine learning-driven platform, PROTiQ. The partnership seeks to address challenges in cell line development such as long development cycles and high failure rates, which can delay regulatory timelines and slow the progression of therapies into clinical settings. By integrating predictive in silico design with rapid experimental validation, the partnership aims to optimize amino acid sequences and identify elite clones with higher productivity, thus enhancing the efficiency and success rate of developing new therapeutic modalities.
Why It's Important?
The partnership between OneCyte and Kemp Proteins is significant for the biopharmaceutical industry as it addresses critical bottlenecks in cell line development. By leveraging advanced technologies such as machine learning and high-throughput single-cell analysis, the collaboration promises to reduce development times and improve yields, which are crucial for the timely delivery of new therapies. This could lead to faster regulatory approvals and quicker access to innovative treatments for patients. The integration of these technologies also represents a shift towards more adaptive and efficient development workflows, which could set new standards in the industry and potentially lower costs associated with drug development.
